Who Owns Recursion Pharmaceuticals Stock?
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 71.60%
- Held by insiders
- 2.04%
- Institutional holders
- 450
- Institutions 71.6%
- Insiders 2.0%
- Public and other 26.4%
Who owns Recursion Pharmaceuticals stock?
Institutional investors own about 71.6% of Recursion Pharmaceuticals's shares, spread across 450 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.04% of RXRX.
The largest institutional holders are Blackrock Inc. (9.40%), ARK Investment Management, LLC (7.72%) and State Street Corporation (6.48%). Together, the top 10 institutions control 46.7% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their RXRX positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RXRX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 50.30M | 9.40% | +16.5% |
| ARK Investment Management, LLC | 41.34M | 7.72% | +2.8% |
| State Street Corporation | 34.71M | 6.48% | +21.8% |
| Vanguard Portfolio Management LLC | 31.13M | 5.82% | +36.8% |
| BAILLIE GIFFORD & CO | 23.49M | 4.39% | -0.8% |
| Vanguard Capital Management LLC | 22.77M | 4.25% | +2.3% |
| Geode Capital Management, LLC | 13.82M | 2.58% | +12.6% |
| Softbank Group Corporation | 13.64M | 2.55% | 0.0% |
| MIC Capital Management UK LLP | 9.64M | 1.80% | 0.0% |
| UBS Group AG | 8.95M | 1.67% | +75.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RXRX
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 23.30M | 4.35% |
| ARK ETF Trust-ARK Innovation ETF | 19.39M | 3.62% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 15.82M | 2.96% |
| ARK ETF Trust-ARK Genomic Revolution ETF | 14.42M | 2.69% |
| iShares Trust-iShares Russell 2000 ETF | 12.94M | 2.42% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 11.42M | 2.13% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 6.56M | 1.22% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 6.01M | 1.12% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 5.59M | 1.04% |
| iShares Trust-iShares Russell 2000 Value ETF | 4.32M | 0.81% |
Frequently asked questions
Who is the largest shareholder of Recursion Pharmaceuticals?
Blackrock Inc. is the largest institutional shareholder of RXRX, owning 9.40% of shares outstanding (50.30M shares) as of its latest 13F filing.
What percentage of Recursion Pharmaceuticals is owned by institutions?
Institutions own about 71.6% of RXRX shares and 73.1% of the public float.
How much of Recursion Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 2.04% of RXRX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.